Hubbry Logo
Health claimHealth claimMain
Open search
Health claim
Community hub
Health claim
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Health claim
Health claim
Health claim
View on Wikipedia
from Wikipedia
fictional illustrative example of baby food packaging
Example of a health claim. In the image, the packaging labeled "C" (first on the right) contains claims related to growth, health, happiness, and improved sleep.

A health claim on a food label and in food marketing is a claim by a manufacturer of food products that their food will reduce the risk of developing a disease or condition.[1] For example, it is claimed by the manufacturers of oat cereals that oat bran can reduce cholesterol, which will lower the chances of developing serious heart conditions. Vague health claims include that the food inside is "healthy," "organic," "low fat," "non-GMO," "no sugar added," or "natural".

Health claims are also made for over-the-counter drugs and prescription drugs, medical procedures, and medical devices, but these generally have a separate, much more stringent set of regulations.

Health claims in the United States

[edit]

In the United States, health claims on nutrition facts labels are regulated by the U.S. Food and Drug Administration (FDA), while advertising is regulated by the Federal Trade Commission.[2] Dietary supplements are regulated as a separate type of consumer item from food or over-the-counter drugs.[citation needed]

Food

[edit]

FDA guidelines

[edit]

According to the FDA, "Authorized health claims in food labeling are claims that have been reviewed by FDA and are allowed on food products or dietary supplements to show that a food or food component may reduce the risk of a disease or a health-related condition."[3][4] An authorized health claim is limited to evidence for reducing the risk of a disease, and does not apply to the diagnosis, cure, mitigation, or treatment of disease.[4] It must be reviewed, evaluated, and publicly-announced by the FDA prior to use.[4]

Approval of a health claim by the FDA requires significant scientific agreement (SSA) among reputable scientists that the claim is based on publicly-available evidence that a relationship exists between an element and a disease.[3][4] The SSA standard provides a high degree of confidence that the relationship between the element and the disease is valid.[3]

Based on scientific evidence, such claims may be used for marketing on foods or dietary supplements.[3] The authorized health claim must be written in a way that helps consumers understand the importance of including the element in their daily diet.[3]

The FDA has guidelines for what is considered a misleading label,[5] and also monitors and warns food manufacturers against labeling foods as having specific health effects when no evidence exists to support such statements, such as for one manufacturer in 2018.[6]

A qualified health claim is supported by some scientific evidence, but does not meet the significant scientific standard of evidence required for an authorized health claim. Qualified health claims must be accompanied by a disclaimer or other qualifying language to accurately communicate the level of scientific evidence supporting the claim.[7]

Consumer advocacy

[edit]

The use of the label “Healthy” on a variety of foods has been a particular issue for many food quality advocacy groups. In general, claims of health benefits for specific foodstuffs are not supported by scientific evidence and are not evaluated by national regulatory agencies. Additionally, research funded by manufacturers or marketers has been criticized to result in more favorable results than those from independently funded research.[8]

Dietary supplements

[edit]

In the United States, these claims, usually referred to as "qualified health claims", are regulated by the Food and Drug Administration (FDA) in the public interest.[9]

The rule in place before 2003 required "significant scientific consensus" before a claim could be made, applying characterization of a hierarchy of degrees of certainty:

  • A: "There is significant scientific agreement for [the claim]."
  • B: "Although there is some scientific evidence supporting [the claim], the evidence is not conclusive."
  • C: "Some scientific evidence suggests [the claim]. However, the FDA has determined that this evidence is limited and not conclusive."
  • D: "Very limited and preliminary scientific research suggests [the claim]. The FDA concludes that there is little scientific evidence supporting this claim."

See the Wikipedia article on dietary supplements for a description of current FDA policy.

Health claims in Canada

[edit]
Main article: Canadian health claims for food

Health claims in Europe

[edit]

In the European Union, the European Food Safety Authority provides regulations on food labeling to address the quality of possible health foods.[10]

In the United Kingdom by law any health claim on food labels must be true and not misleading. Food producers may optionally use the (discontinued in 2010) Joint Health Claims Initiative to determine whether their claims are likely to be legally sustainable.[citation needed]

In early 2005 the European PASSCLAIM project (Process for the Assessment of Scientific Support for Claims on Foods), sponsored by the European Union and coordinated by ILSI-Europe (https://web.archive.org/web/20090822045739/http://europe.ilsi.org/), ended. The aim of this project was to develop criteria for the scientific substantiation of claims on foods. Several hundreds of scientists from academia, research institutes, government and industry have contributed to the project. All the resulting papers can be downloaded for free from http://www.ilsi.org/Europe/Pages/PASSCLAIM_Pubs.aspx. The final consensus paper, comprising the final set of criteria, has been published in June 2005 in the European Journal of Nutrition.[11]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Health claim

View on Grokipedia
from Grokipedia
A health claim is any assertion in labeling, , or that links the consumption of a , , dietary ingredient, or supplement to a beneficial effect on , such as reducing the of a specific or health-related condition. These claims are distinguished from nutrient content claims, which describe the level of a in a product, and structure/function claims, which describe effects on the body's normal or function without referencing prevention or treatment. In jurisdictions like the and , authorized health claims require pre-market regulatory approval to ensure they are supported by sufficient , aiming to protect consumers from unsubstantiated promises while allowing informative labeling. Regulatory frameworks, such as those from the U.S. Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA), classify health claims into categories like disease risk reduction claims, which must demonstrate a causal relationship between intake and lowered disease incidence, and general function claims, which pertain to maintenance of normal bodily processes. Approval hinges on the totality of publicly available scientific evidence, prioritizing randomized controlled trials and meta-analyses over observational studies to establish causality rather than mere correlation. Notable examples of authorized claims include associations between adequate calcium intake and reduced osteoporosis risk or folate consumption and lowered neural tube defect incidence, though the number of such validated claims remains limited due to stringent standards. Unauthorized or qualified claims, permitted under certain conditions with disclaimers, highlight ongoing debates over evidence thresholds, as weaker substantiation can lead to qualified language acknowledging incomplete proof. Despite regulatory oversight, health claims have sparked controversies over their potential to mislead consumers, particularly when based on preliminary or industry-funded prone to or when extrapolated from models to s without robust human trials. Empirical reveals that many proposed claims fail to meet causal criteria, as nutritional interventions often involve multifactorial influences like dosage, population variability, and long-term adherence, complicating definitive proof. This underscores the emphasis on high-quality, reproducible to distinguish genuine benefits from hype, with violations of claim regulations resulting in enforcement actions to curb deceptive marketing.

Definition and Classification

A health claim refers to a statement linking a , food component, , or ingredient to a specific benefit, typically involving the reduction of risk or improvement in a health-related condition, distinct from mere nutritional composition or general wellness assertions. These claims must be substantiated by to avoid misleading consumers, with core concepts emphasizing between the substance and outcome rather than alone, often requiring demonstration of mechanisms like nutrient-disease interactions grounded in human clinical data. Key distinctions include structure/function claims, which describe a nutrient's role in maintaining normal bodily structure or function (e.g., "calcium builds strong bones") without implying disease prevention, and thus face fewer regulatory hurdles than health claims. Nutrient content claims, such as "low sodium" or "high in fiber," focus solely on quantitative levels of nutrients or ingredients without health outcome linkages. Health claims, by contrast, inherently invoke therapeutic or preventive implications, necessitating rigorous evidentiary thresholds to establish that the claimed relationship holds under typical consumption conditions. In the United States, the (FDA) defines a health claim under 21 CFR 101.14 as any label or labeling assertion—express or implied—that characterizes the relationship between a substance in a or and a or health-related condition, excluding drug-like treatment claims which trigger separate pharmaceutical regulations. Such claims require FDA via the Significant Scientific Agreement (SSA) standard, demanding consensus from qualified experts on the totality of publicly available evidence, or qualified health claims for emerging evidence with disclaimers (e.g., "may reduce risk"). Unauthorized health claims render products misbranded under the Federal Food, Drug, and Cosmetic Act, potentially leading to enforcement actions. In the , Regulation (EC) No 1924/2006 establishes health claims as any representation suggesting a or its constituent relates to health, categorized into general function claims (Article 13, e.g., nutrient roles in bodily processes) and those for risk reduction or (Article 14). The (EFSA) assesses claims for scientific substantiation, authorizing only those supported by human intervention studies or equivalent data showing , with conditions of use specified (e.g., daily intake amounts). Claims lacking approval are prohibited, aiming to harmonize labeling across member states while prioritizing consumer protection from unsubstantiated assertions.

Types of Claims

Health claims on food and dietary supplements are broadly classified into categories that distinguish between descriptions of levels, effects on bodily functions, and relationships to risk, with variations by to ensure scientific substantiation and prevent misleading consumers. In the United States, the (FDA) delineates three primary types of label claims: content claims, structure/function claims, and health claims. content claims specify the presence or quantity of a or dietary substance relative to established reference values, using terms such as "high," "low," "free," or comparative phrases like "reduced" or "more," provided the product meets predefined thresholds (e.g., at least 20% of the Daily Value for "high" in a ). These claims focus solely on nutritional composition without implying health outcomes. Structure/function claims, permissible for both conventional foods and dietary supplements under the Federal Food, Drug, and Cosmetic Act, assert the intended role of a or dietary ingredient in affecting the body's normal structure or function, such as " maintains bowel regularity" or "antioxidants protect cells from ." Unlike disease-related assertions, these do not require pre-market FDA approval but must be truthful, not misleading, and include a mandatory on supplements stating that the claim has not been evaluated by the FDA and the product is not intended to diagnose, treat, cure, or prevent . Such claims cannot suggest prevention, treatment, or mitigation of , as that would classify them as unauthorized drug claims, which are prohibited without FDA approval as new drugs. Health claims proper, which explicitly link a , food component, or supplement to reducing the of a specific or health-related condition (e.g., "adequate calcium may reduce the risk of "), demand rigorous and FDA oversight. These are subdivided into authorized health claims, supported by significant scientific agreement from qualified experts reviewing the totality of , and qualified health claims, permitted for emerging that falls short of full agreement but meets a lower "credible " threshold, often phrased with qualifiers like "some suggests" (e.g., "FDA concludes that nuts may reduce heart "). As of 2024, the FDA has authorized 14 health claims, such as the relationship between folic acid and defects, while qualified claims number fewer and require petition-based review. In the European Union, Regulation (EC) No 1924/2006 similarly separates nutrition claims (e.g., "low fat" or "source of fiber," akin to U.S. nutrient content claims) from health claims, which must be authorized by the following scientific assessment by the (EFSA). EU health claims encompass function claims, describing the role of a nutrient or substance in growth, development, or normal bodily functions (e.g., " contributes to the normal function of the "), and risk-reduction claims, indicating a food can reduce the risk of a when consumed as part of a balanced diet (e.g., "plant sterols can lower "). By 2022, over 4,000 submitted claims had been evaluated, with only about 250 authorized, emphasizing strict substantiation via human intervention studies or equivalent evidence. Claims implying treatment or cure remain unauthorized and treated as medicinal assertions, subject to pharmaceutical regulations. Other jurisdictions, such as and /, adopt hybrid approaches: permits general diet-disease risk reduction claims with approval, while classifies as general () or therapeutic (disease-specific) claims under Food Standards , requiring varying evidence levels. Across regions, a key distinction persists between permissible claims grounded in normal or modulation versus impermissible ones implying therapeutic , reflecting efforts to balance consumer information with protection against unsubstantiated promises.

Scientific Foundations

Evidence Requirements

Regulatory authorities mandate that health claims be substantiated by robust demonstrating a cause-and-effect relationship between a food, food component, or dietary pattern and a specific benefit or risk reduction, with intervention studies—particularly randomized controlled trials (RCTs)—serving as the gold standard due to their capacity to establish while controlling for confounders and biases. The totality of publicly available evidence is assessed, weighing factors such as study design quality, relevance to the target population, statistical power, dose-response relationships, biological plausibility, and consistency across independent replications, while discounting or downweighting lower-quality data like case reports, experiments, or animal models that lack direct applicability. In the United States, the Food and Drug Administration (FDA) applies the Significant Scientific Agreement (SSA) standard, requiring broad consensus among qualified experts that the evidence supports the claim without substantial unresolved disagreement, as determined by systematic review of peer-reviewed publications rather than proprietary data alone. This threshold, established under the Nutrition Labeling and Education Act of 1990, prioritizes RCTs with adequate sample sizes and duration to detect meaningful effects, alongside supportive observational data only if corroborated by intervention trials; claims failing SSA may qualify for qualified health claims with disclaimers if evidence shows potential benefit but lacks consensus. The (EFSA) enforces a comparable "generally accepted " criterion under Regulation (EC) No 1924/2006, demanding pertinent, reliable human data from at least two independent, high-quality studies showing a beneficial physiological effect under defined conditions of use, with no by other factors and applicability to the general healthy or subgroups. EFSA's assessments, conducted within five months of application validation, emphasize unconfounded intervention trials using validated biomarkers or clinical endpoints, rejecting claims where is preliminary, inconsistent, or derived solely from mechanistic studies. Internationally, guidelines align with these principles, stipulating that health claims require sufficient current scientific substantiation tailored to the claim's type—such as reduced disease risk—prioritizing human clinical evidence over epidemiological associations, which are susceptible to residual and reverse causation. Observational studies, while useful for generation, rarely suffice independently, as they cannot reliably infer without triangulation via RCTs; regulatory scrutiny also extends to study funding sources for potential , though peer-reviewed replication remains paramount. For claims involving long-term outcomes like , prospective cohort may supplement but must align with trial results, ensuring claims reflect verifiable, non-misleading benefits.

Evaluation Methods and Challenges

Scientific evaluation of health claims relies on systematic assessment of the totality of publicly available evidence, with a preference for human intervention studies demonstrating . Regulatory bodies such as the U.S. Food and Drug Administration (FDA) employ an evidence-based review system that involves identifying key scientific questions, conducting comprehensive searches, evaluating based on factors like study design and , determining the direction and consistency of effects, and weighing the overall strength of evidence against standards like significant scientific agreement (SSA) for unqualified claims or emerging evidence for qualified claims. The (EFSA) similarly requires substantiation through a hierarchy prioritizing randomized controlled trials (RCTs) supplemented by dose-response data and validated biomarkers, rejecting claims without consistent, robust human data. Evidence hierarchies rank systematic reviews and meta-analyses of RCTs highest, followed by individual RCTs, cohort studies, and mechanistic data, ensuring claims reflect reproducible effects rather than associative or preclinical findings. Challenges in evaluation stem from inherent limitations in generating high-quality evidence for dietary and supplement claims. RCTs, the gold standard, often face practical barriers such as ethical constraints on withholding nutrients, high costs, and participant adherence issues in long-term trials needed for chronic disease outcomes, leading to underpowered or short-duration studies. Confounding variables like overall diet, , and complicate isolation of specific ingredient effects, while strain- or dose-specificity in and botanicals demands targeted, reproducible data that many submissions lack. EFSA's rejection rate exceeds 90% for novel claims, frequently due to inconsistent results across heterogeneous populations or reliance on surrogate endpoints without clinical relevance. Additional hurdles include favoring positive outcomes and potential conflicts from industry-funded research, which meta-analyses show are more likely to report favorable results without adjusting for sponsorship effects. Regulatory thresholds like FDA's SSA or EFSA's "convincing" evidence may diverge from evolving , delaying approvals for claims with suggestive but not definitive data, while enforcement gaps allow unsubstantiated marketing. Variability in global standards further complicates cross-jurisdictional evaluation, as U.S. qualified claims permit weaker evidence than EU authorizations.

Historical Development

Pre-Modern and Early Regulatory Efforts

In ancient Rome, medical practice was subject to social and legal constraints rather than systematic regulation of claims, with physicians from elite classes facing penalties such as infamia (public disgrace) for negligence or incompetence, while those from lower strata encountered fewer formal repercussions. General Roman fraud laws, including those against calumnia (malicious false accusations), provided indirect recourse against deceptive practices, though no dedicated statutes targeted health claims explicitly. During the medieval period, regulatory efforts emphasized licensing to curb unqualified practitioners making unsubstantiated health assertions. In 1140, enacted the first known European law prohibiting medical practice without royal authorization, establishing examinations and penalties for violations to protect against charlatans. Similarly, under ancient Irish Laws, patients or families could litigate physicians for or ineffective treatments, imposing fines or restitution based on harm caused, reflecting community-driven accountability absent centralized enforcement. Professional guilds and emerging universities, such as Montpellier's anatomy school by 1340, further standardized training, implicitly challenging folk remedies and unverified claims by privileging learned practitioners. In , particularly , guilds like the Royal College of Physicians—chartered in 1518—exercised monopolistic control in , prosecuting "irregulars" for unlicensed practice and exaggerated therapeutic promises through fines, , or expulsion. The Worshipful Society of Apothecaries, formalized later, reinforced this by regulating compounders against adulteration and false labeling. By the , fiscal measures served as regulation: the 1783 Medicine required vendors of proprietary remedies to obtain annual licenses and affix duty stamps, aiming to monitor and tax while generating revenue, though enforcement favored legitimate sellers over outright bans. saw analogous guild restrictions and princely edicts, such as in German states, where suppressed itinerant mountebanks peddling unproven cures, yet pervasive advertising in pamphlets persisted with minimal claim-specific oversight until the . These efforts prioritized practitioner credentials over product , often tolerating bold testimonials as long as taxes were paid, highlighting causal tensions between revenue needs and public protection.

Modern Milestones and Shifts

The Nutrition Labeling and Education Act (NLEA) of 1990 marked a pivotal shift in the United States by mandating nutrition labeling on most packaged foods and authorizing health claims linking diet to disease reduction or risk, provided they met the FDA's significant scientific agreement (SSA) standard based on consistent evidence from authoritative sources. This legislation responded to growing consumer interest in diet-disease relationships, exemplified by the 1984 Kellogg campaign promoting high-fiber cereals for , which intensified debates over claim substantiation and led to standardized criteria to prevent misleading assertions. The Health and Education Act (DSHEA) of 1994 further expanded the landscape by classifying dietary supplements as foods rather than drugs, permitting structure/function claims—such as statements on roles in maintaining bodily functions—without pre-market FDA approval, though requiring substantiation with competent and reliable . This act, signed amid industry pushback against stringent drug-like oversight, allowed claims like "calcium builds strong bones" but prohibited disease treatment implications, fostering market growth while imposing post-market enforcement responsibilities on the FDA and FTC. In the , Regulation (EC) No 1924/2006 on and claims, adopted in 2006 and implemented from 2007, represented a harmonization milestone by requiring all claims to be scientifically substantiated, with claims (those referencing disease prevention or risk reduction) needing pre-authorization by the (EFSA) based on rigorous evidence, often from human intervention studies. By 2012, the EU approved a list of 222 permitted claims, emphasizing nutrient-specific effects, while rejecting unsubstantiated ones like many assertions due to insufficient data. Subsequent shifts reflect heightened evidentiary demands globally: U.S. FTC guidance in 2022 reiterated that health claims require "competent and reliable scientific evidence," typically two well-controlled human clinical trials for material claims, amid enforcement actions like the case underscoring randomized controlled trials' primacy over weaker evidence. In the , a 2020 NHCR evaluation highlighted ongoing tensions over profiles to restrict claims on unhealthy foods, influencing the 2019 Farm to Fork Strategy's push for evidence-based innovation amid critiques of over-reliance on EFSA's conservative thresholds, which have limited novel claims despite industry-submitted dossiers exceeding 4,000 applications. These developments underscore a transition from permissive, descriptive claims to causal, data-driven substantiation, balancing with while exposing gaps in adapting to emerging fields like personalized .

Global Regulatory Approaches

United States Framework

The regulatory framework for health claims in the distinguishes between labeling for conventional foods and dietary supplements, with the (FDA) holding primary authority over label claims under the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Nutrition Labeling and Education Act (NLEA) of 1990. The NLEA established that health claims—statements linking a food substance to reduced risk of a or health-related condition—must be authorized by FDA through regulations based on the "significant scientific agreement" (SSA) standard, evaluating the totality of publicly available . Claims lacking such substantiation are prohibited as misbranding, with FDA enforcing via inspections, warning letters, and seizures. For conventional foods, FDA has authorized 13 health claims meeting the SSA threshold as of 2024, such as the relationship between soluble fiber from oats and reduced coronary heart disease risk, requiring specific wording and qualifying conditions like daily intake amounts. Qualified health claims, introduced following a 2002 federal court ruling in Pearson v. Shalala, allow limited use for emerging evidence not reaching SSA, subject to FDA's letters of enforcement discretion and mandatory qualifiers like "supportive but not conclusive research shows." Examples include "eating nuts (such as pistachios) may reduce the risk of heart disease" or, as of May 2024, "eating regularly, at least two cups per week, may reduce the risk of ." These require petition submission with scientific data, but FDA approval is discretionary and rare, prioritizing against unsubstantiated implications. Dietary supplements, regulated under the Dietary Supplement Health and Education Act (DSHEA) of 1994, permit structure/function claims without premarket FDA approval, provided they describe effects on the body's normal structure or function (e.g., "calcium builds strong bones") rather than disease prevention, treatment, or diagnosis. Such claims must be truthful, not misleading, substantiated by competent and reliable scientific evidence, and accompanied by a prominent disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." DSHEA shifted the burden from pre-approval to post-market enforcement, allowing manufacturers greater flexibility but increasing FDA's monitoring for disease claim crossovers, which reclassify products as unapproved drugs. The (FTC) complements FDA by regulating advertising claims across all media, requiring substantiation with "competent and reliable " proportional to the claim's specificity, such as at least two adequate and well-controlled human studies for risk reduction assertions. The FTC warns against dietary supplements lacking reliable evidence, particularly those making claims that cross into unapproved disease treatment territory, such as managing diabetes symptoms. FTC-FDA coordination addresses jurisdictional overlaps, with FTC targeting deceptive ads for foods, supplements, and over-the-counter drugs via consent orders, civil penalties, and consumer redress, as in cases involving unsubstantiated or immunity claims. Enforcement gaps persist due to resource constraints and evolving , though FTC's 2022 Health Products Compliance Guidance emphasizes rigorous evidence over mere citations to advisories. Overall, the framework balances innovation with evidence-based safeguards, though critics note SSA's stringency may stifle emerging science while structure/function leniency risks consumer confusion.

European Union Standards

The 's standards for health claims on s are primarily governed by Regulation (EC) No 1924/2006, adopted on 20 December 2006 and applicable from 1 July 2007, which harmonizes rules across member states to ensure claims are clear, substantiated, and not misleading to consumers. The regulation applies to nutrition and health claims made in commercial communications, including labelling, presentation, and advertising of foods, while excluding non-commercial communications such as information in the press and scientific publications. Claims must be substantiated by generally accepted scientific evidence. Personal stories and testimonials do not qualify as such evidence and cannot substantiate health claims under the regulation. Books containing personal stories or testimonials are generally exempt if they are non-commercial and do not promote specific foods commercially. The regulation distinguishes between nutrition claims (e.g., "low fat" or "high fibre," permitted only if meeting predefined thresholds in the annex) and health claims (asserting a relationship between or its components and health outcomes, such as maintenance of normal function or disease risk reduction), requiring the latter to undergo pre-market authorisation based on . Health claims are categorized under Articles 13 and 14 of the regulation: Article 13(1) covers general functions (e.g., "calcium helps maintain normal bone health"); Article 13(5) addresses risk reduction or child development; and Article 14 includes disease risk reduction (e.g., sodium's role in blood pressure) or claims implying prevention/cure of disease, which are prohibited unless authorised. Authorisation demands "scientifically substantiated" claims, assessed by the European Food Safety Authority (EFSA) for the highest level of evidence, typically requiring human intervention studies demonstrating causality, dose-response, and applicability to the general population rather than specific subgroups. Claims must also be understandable by the average consumer, with mandatory conditions like target population intake levels specified. The authorisation process begins with applicants submitting dossiers to a member state's , which forwards them to EFSA for a scientific opinion within six months; EFSA evaluates evidence for , , and , often rejecting applications lacking robust, peer-reviewed human data (with over 2,300 claims assessed and approximately 90% non-authorised to date). Positive EFSA opinions lead to the European Commission's proposal for an implementing act, adopted via qualified majority in the Standing Committee on Plants, Animals, and Feed, and published in the Journal; authorised claims enter the EU Register, mandatory for use across the , while non-authorised ones are prohibited. Member states enforce compliance through national laws, with penalties for unsubstantiated claims, though implementation varies, as noted in a 2023 study highlighting gaps in botanical claims authorisation due to stringent evidentiary demands. No substantive amendments to Regulation 1924/2006 have altered core standards as of 2025, though ongoing evaluations address emerging evidence and enforceability, maintaining a precautionary approach prioritising consumer protection over unproven assertions.

Other Jurisdictions

In , health claims on labels have been regulated under the Food and Drugs Regulations since amendments in 2002, permitting a limited set of pre-approved disease risk reduction claims substantiated by scientific evidence from . Only five such claims are authorized, including those linking diets low in sodium to reduced risk of and high in and fruits to lowered cancer risk, with products required to meet specific criteria like at least 5% of daily recommended intake for certain vitamins. Disease treatment or cure claims remain prohibited for foods to avoid overlap with regulations. Australia and New Zealand oversee health claims through Food New Zealand (FSANZ) under Standard 1.2.7 of the Food Standards Code, effective since January 2013, which mandates compliance with a Profiling Scoring Criterion (NPSC) to exclude high-sugar, high-fat, or high-sodium foods from bearing claims. Claims must be supported by demonstrating a degree of certainty, with options for pre-approval by FSANZ or self-substantiation by manufacturers, covering general-level claims (e.g., roles) and higher-level claims (e.g., risk reduction). Japan's system for Foods with Health Claims (FHC), established by the Ministry of , Labour and Welfare, categorizes products into Foods for Specified Health Uses (FOSHU, approved since with rigorous review), Foods with Nutrient Function Claims (self-certified for standard nutrients), and Foods with Function Claims (FFC, introduced in 2015 for self-substantiated benefits based on scientific data submitted to authorities). FFC allows claims for any food type, including supplements, provided evidence supports effects like improved or , with recent 2024 amendments requiring hazard information and GMP compliance. In , health foods—distinct from ordinary foods—are regulated by the (SAMR) under a 2016 framework requiring registration for claims involving 27 approved functions (e.g., immune enhancement, vision protection) or filing for / supplements, with mandatory toxicological and testing. Only regulator-approved claims are permitted, emphasizing scientific substantiation to prevent unsubstantiated promotion, amid ongoing updates like potential addition of joint health claims in 2025. Post-Brexit, the retains elements of Regulation (EC) No 1924/2006 via the Nutrition and Health Claims Register managed by the , authorizing claims only if pre-approved and evidenced, with -authorized claims valid in but subject to UK-specific validation for new submissions. adheres to rules under the , creating divergence where novel claims require separate UK assessment to ensure substantiation. Internationally, the Commission provides non-binding guidelines on nutrition and health claims, adopted in 2004 and updated through 2009, requiring claims to be truthful, not misleading, and backed by of a significant effect, influencing national standards while allowing flexibility for function or risk reduction assertions.

Controversies and Debates

Regulatory Overreach vs. Market Freedom

The debate over regulatory overreach in claims centers on whether stringent pre-market approvals and enforcement stifle legitimate innovation and consumer access to information, or whether such measures are essential to curb deception. Proponents of market freedom argue that excessive imposes prohibitive evidentiary burdens, such as randomized controlled trials for probabilistic benefits, which disproportionately burden small firms and delay dissemination of emerging scientific insights. For instance, under the U.S. Health and Education Act of 1994, structure/function claims (e.g., "calcium supports ") require substantiation but not FDA pre-approval if truthful and not misleading, fostering a $50 billion supplement industry by 2023 while relying on post-market enforcement like warning letters for violations. In contrast, critics of lax oversight highlight risks of unsubstantiated claims misleading consumers, as evidenced by FTC and FDA actions against products implying disease prevention without adequate evidence, such as in 2020 warning letters to seven firms for treatments. Empirical assessments suggest overregulation can hinder innovation without commensurate public health gains. A 2016 study on the EU's Nutrition and Health Claims Regulation (NHCR), implemented in 2006, found it blocked product innovation by rejecting claims with observational or mechanistic evidence, reducing authorized claims to approximately 260 by 2023 despite initial submissions of over 44,000, with more than 70% deemed unsubstantiated by the (EFSA). This contrasts with the U.S. approach permitting qualified health claims for weaker but scientifically supported associations, such as "supportive evidence suggests but does not prove" for certain nutrients, enabling broader market signaling without exhaustive RCTs. Market advocates contend that reputational incentives, private litigation, and consumer discernment—augmented by third-party testing—provide causal checks on false claims more efficiently than bureaucratic gatekeeping, which often favors large incumbents able to navigate compliance costs exceeding $100,000 per claim evaluation. Regulatory proponents counter that market failures in asymmetric information necessitate intervention, pointing to surveys where consumers misinterpret vague claims on supplements as disease cures. However, causal analysis reveals limited correlation between claim restrictions and improved outcomes; for example, EU obesity rates remained stable or rose post-NHCR despite fewer claims, suggesting regulations may obscure valid nutritional guidance rather than enhance it. Instances of perceived FDA overreach, such as aggressive scrutiny of implied disease claims in supplement labeling (e.g., equating "supports immune function" with unapproved drug status), illustrate how binary disease vs. structure/function distinctions can suppress non-pharmaceutical options, potentially channeling consumers toward costlier patented interventions. Ultimately, evidence tilts toward calibrated deregulation: allowing claims backed by competent scientific agreement promotes informed choice and incentivizes voluntary evidence-building, as seen in Japan's Foods with Function Claims system, which approved over 1,000 products since 2015 by lowering thresholds for substantiated benefits.

False Claims, Fraud, and Enforcement Gaps

Numerous dietary supplements marketed with health claims have been found to contain unapproved or unsubstantiated assertions, including treatment or prevention claims prohibited under U.S. law without FDA approval. For instance, the FDA has identified over 1,050 tainted dietary supplements since 2007, many adulterated with synthetic drugs like medications or anabolic steroids to mimic health benefits, while labels falsely imply safety and efficacy. Structure/function claims, such as "supports heart health," require no pre-market authorization but demand competent for substantiation; however, a 2012 HHS Office of Inspector General review of 12 firms found that documents for sampled products often lacked reliable evidence, relying instead on anecdotal testimonials or flawed studies inconsistent with FDA guidance. Fraudulent schemes have proliferated, exemplified by cases where companies illegally claimed supplements cured serious conditions like cancer or COVID-19. In , five individuals and two companies pleaded guilty to charges in a multimillion-dollar involving adulterated supplements sold as treatments for and , resulting in FDA seizures and criminal penalties. The (FTC) has pursued over 120 enforcement actions against supplement makers for deceptive health claims, including a 2010 settlement where Iovate Health Sciences paid $5.5 million for falsely advertising products like as aiding substantial without adequate , and misrepresenting MD as homeopathic. More recently, in 2024, a federal court prohibited Quincy Bioscience from claiming its Prevagen supplement improves memory or brain function, following FTC and New York AG suits that highlighted unsubstantiated jellyfish-derived protein assertions despite failures. Enforcement gaps persist due to regulatory limitations and resource constraints, allowing many violators to continue operations post-warning. The FDA primarily issues warning letters—over 100 annually for health fraud—rather than mandatory recalls for supplements, as pre-market review is absent except for new dietary ingredients, and post-market surveillance relies on voluntary reporting amid an industry exceeding $50 billion in U.S. sales. A 2009 report identified coordination failures between FDA and USDA in enforcement, including health claims, with inadequate tracking of violations leading to repeated non-compliance. In the , while Regulation (EC) No 1924/2006 mandates scientific substantiation for nutrition and health claims, enforcement varies by member state, with fragmented oversight and limited penalties exacerbating gaps in detecting unauthorized claims or adulteration. These shortcomings enable persistent market presence of fraudulent products, as seen in the FDA's ongoing health fraud database listing hundreds of unapproved items still promoted online despite citations.

Tension Between Science and Innovation

Scientific validation of health claims necessitates high-quality evidence, such as randomized controlled trials demonstrating , to prevent consumer deception and ensure safeguards. However, this evidentiary threshold often conflicts with imperatives in the nutraceutical and sectors, where developers seek to commercialize products based on emerging preclinical or observational data before exhaustive human studies are feasible. Regulatory processes demanding conclusive proof impose significant financial and temporal burdens—costs for clinical substantiation can exceed millions of euros per claim—potentially discouraging investment in novel ingredients like or bioactive compounds. In the , the (EFSA) exemplifies this tension through its stringent pre-market authorization under (EC) No 1924/2006, which has approved fewer than 300 health claims since 2006 while rejecting around 90% of submissions due to insufficient causal evidence. Such rigor has been critiqued for stifling innovation, as the evaluation process under (EU) 2015/2283 frequently exceeds nine-month statutory timelines, with median delays of over 18 months for 292 applications analyzed from 2018 to 2024, thereby impeding market access for potentially beneficial products. Industry analyses indicate this framework favors established nutrient claims over innovative botanicals or synbiotics, limiting European competitiveness against more permissive jurisdictions. Conversely, the U.S. (FDA) adopts a more innovation-friendly approach by allowing structure/function claims for dietary supplements—asserting effects on body structure or function without disease treatment implications—without mandatory pre-approval, provided they are truthful and not misleading. This flexibility has facilitated rapid proliferation of over 85,000 supplement products by 2018, yet it invites criticism for enabling unsubstantiated assertions lacking robust trials, as evidenced by enforcement actions against fraudulent claims in the sector. Comparative studies highlight that while FDA's qualified health claims permit lower evidence tiers (e.g., "may reduce risk" based on inconsistent data), EFSA's binary approval model prioritizes but correlates with reduced R&D incentives, with innovation lagging in relative to . Efforts to reconcile these poles include proposals for tiered claims—provisional labels for preliminary evolving to substantiated status—or streamlined reviews for low- innovations, as advocated in policy discussions on . Empirical outcomes remain mixed: strict regimes like EFSA's have minimized false claims but yielded only four authorized claims by 2021, potentially overlooking benefits from adaptive research, whereas permissive systems risk eroding trust through scandals like undeclared adulterants in supplements. Ultimately, causal realism underscores that optimal calibrates demands to product profiles, fostering verifiable without compromising .

Impacts and Outcomes

Effects on Public Health and Consumer Behavior

Health claims on and packaging, such as those promising relief from , , or digestive discomfort, substantially shape parental purchasing decisions. Experimental studies demonstrate that parents perceive products with such claims as healthier and more suitable for infants, increasing selection rates even for ultra-processed items that fail nutritional benchmarks. For example, claims implying "comfort for baby" or reduced drive preferences for commercial foods over homemade alternatives, with removal of these claims reducing parental endorsement of unhealthy options. These marketing tactics often prioritize perceived efficacy over evidence, leading consumers to favor products with additives like simethicone or despite inconsistent substantiation. Simethicone, commonly featured in gas-relief claims, shows no efficacy in treating infantile , while exhibit limited benefits primarily in breastfed infants, with insufficient data for formula-fed ones. Parents' trust in packaging assertions correlates with higher expenditures on such items, potentially sidelining behavioral interventions like dietary adjustments or professional advice. On , unsubstantiated claims erode initiation and continuation by portraying formula variants as superior for specific ailments, despite formula's inherent risks relative to , including altered and increased infection susceptibility. Regulatory analyses across multiple countries reveal that over 90% of reviewed claims lack robust supporting evidence, fostering over-reliance on commercial products that may mask underlying conditions like allergies or intolerances. This dynamic contributes to suboptimal , as evidenced by widespread non-compliance with WHO protein and calorie guidelines in marketed baby foods bearing health assertions. Aggressive promotion via claims has broader implications, with surveys indicating over half of parents encounter targeted that amplifies formula's appeal, potentially delaying medical consultations and exacerbating colic-related distress without causal resolution. While some strains reduce crying time by 25-65 minutes daily in select cohorts, the absence of standardized efficacy across products underscores risks of false reassurance, where unproven interventions supplant evidence-based care like parental reassurance or hydrolyzed formulas when indicated.

Economic and Industry Implications

The allowance of substantiated health claims on food and supplement products has fueled significant market expansion in the functional foods and nutraceuticals sectors, enabling and differentiation based on purported benefits like improved or immune support. The global functional foods market, which often relies on approved health claims for marketing, was valued at USD 337.85 billion in 2024 and is projected to reach USD 595.49 billion by 2033, reflecting a compound annual growth rate driven by demand for products with nutrient-specific claims. Similarly, the dietary supplement industry, where structure-function claims are permitted under frameworks like the U.S. , generated an overall economic impact of USD 159 billion in 2023, supporting jobs and innovation in formulation and distribution. Regulatory hurdles for validating health claims, however, impose substantial compliance costs on manufacturers, including expenses for clinical trials, scientific dossiers, and legal reviews to meet standards set by bodies like the FDA or EFSA. In the European Union, the Nutrition and Health Claims Regulation (EC) No 1924/2006 has led to widespread claim rejections—over 90% of submitted general function claims under Article 13.1 were not authorized—resulting in product reformulations, labeling changes, and market withdrawals that disproportionately burden small and medium-sized enterprises in the food supplement sector. An independent assessment estimated these regulatory impacts as largely negative, with industry surveys indicating substantial economic losses from restricted marketing and innovation delays. In contrast, the U.S. system's qualified health claims, which allow lower-evidence statements with disclaimers, facilitates broader industry access but still requires notification and monitoring, contributing to ongoing FTC enforcement against unsubstantiated claims. False or misleading health claims expose companies to litigation and enforcement actions, amplifying financial risks through settlements, fines, and that can deter in borderline products. The FTC has pursued over 120 cases in the past decade against deceptive health for foods and supplements, often resulting in corrective and consumer redress exceeding millions per case, while class-action lawsuits under state laws further escalate costs for unsubstantiated or assertions. These liabilities incentivize self-regulation and third-party verification but also contribute to industry consolidation, favoring large firms with resources for compliance over smaller innovators. Overall, while health claims regulations promote evidence-based growth—evident in the nutraceuticals market's projected rise to USD 709.5 billion by 2034—they create barriers that may suppress unsubstantiated but potentially viable products, yielding a net economic tension between and market dynamism.

References

  1. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/questions-and-answers-health-claims-food-labeling
  2. https://www.efsa.europa.eu/en/topics/topic/health-claims
  3. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/label-claims-conventional-foods-and-dietary-supplements
  4. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/authorized-health-claims-meet-significant-scientific-agreement-ssa-standard
  5. https://www.efsa.europa.eu/en/topics/health-claims-art-13
  6. https://www.eufic.org/en/healthy-living/article/what-are-nutrition-and-health-claims
  7. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-evidence-based-review-system-scientific-evaluation-health-claims
  8. https://www.raps.org/news-and-articles/news-articles/2018/7/evaluating-science-for-health-claims-an-evolving
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC2606982/
  10. https://www.sciencedirect.com/science/article/pii/S0022316622098431
  11. https://www.researchgate.net/publication/298596276_Health_claims_What_are_the_evidence-based_facts_Requirements_for_the_documentation_of_health-promoting_properties_of_foods
  12. https://food.ec.europa.eu/food-safety/labelling-and-nutrition/nutrition-and-health-claims/health-claims_en
  13. https://www.efsa.europa.eu/en/safe2eat/health-claims
  14. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/structurefunction-claims
  15. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-A/section-101.14
  16. https://www.efsa.europa.eu/en/topics/health-claims-art-14
  17. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/label-claims-food-dietary-supplements
  18. https://nationalaglawcenter.org/the-legality-of-food-labeling-claims-fdas-regulations/
  19. https://food.ec.europa.eu/food-safety/labelling-and-nutrition/nutrition-and-health-claims_en
  20. https://www.raps.org/news-and-articles/news-articles/2022/9/nutrition-and-health-claims-in-the-european-union
  21. https://ift.onlinelibrary.wiley.com/doi/10.1111/1541-4337.12716
  22. https://www.sciencedirect.com/science/article/pii/S1756464620301201
  23. https://www.efsa.europa.eu/sites/default/files/event/101202/nda101202-p02.pdf
  24. https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2021.6553
  25. https://www.fao.org/input/download/standards/351/CXG_023e.pdf
  26. https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4680
  27. https://pubmed.ncbi.nlm.nih.gov/20137056/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC12071930/
  29. https://www.exponent.com/article/substantiating-eu-health-claim-submissions
  30. https://jn.nutrition.org/article/S0022-3166%2822%2909086-1/fulltext
  31. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/qualified-health-claims
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC10408696/
  33. https://www.metmuseum.org/essays/medicine-in-the-middle-ages
  34. https://blogs.gwu.edu/himmelfarb/2022/03/16/ancient-medieval-irish-medical-history/
  35. https://www.historytoday.com/archive/feature/quack-medicine-georgian-england
  36. https://www.culturenlmuseums.co.uk/story/quack-medicine/
  37. https://www.ncbi.nlm.nih.gov/books/NBK293691/
  38. https://academic.oup.com/book/44294/chapter/372644109
  39. https://www.ncbi.nlm.nih.gov/books/NBK209859/
  40. https://ods.od.nih.gov/About/DSHEA_Wording.aspx
  41. https://ec.europa.eu/food/safety/labelling_nutrition/claims_en
  42. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
  43. https://www.congress.gov/crs-product/IF12801
  44. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/qualified-health-claims-letters-enforcement-discretion
  45. https://www.fdli.org/2024/05/fda-announces-qualified-health-claim-for-yogurt-and-reduced-risk-of-type-2-diabetes/
  46. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-structurefunction-claims
  47. https://www.ftc.gov/business-guidance/advertising-marketing/health-claims
  48. https://www.ftc.gov/news-events/news/press-releases/2021/09/ftc-sends-cease-desist-demands-10-companies-suspected-making-diabetes-treatment-claims-without
  49. https://www.ftc.gov/news-events/topics/truth-advertising/health-claims
  50. https://www.congress.gov/crs_external_products/R/PDF/R48623/R48623.1.pdf
  51. https://eur-lex.europa.eu/eli/reg/2006/1924/oj/eng
  52. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32006R1924
  53. https://food.ec.europa.eu/food-safety/labelling-and-nutrition/nutrition-and-health-claims/nutrition-claims_en
  54. https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2021.6554
  55. https://www.efsa.europa.eu/sites/default/files/applications/apdeskapplworkflownutrihealthclaims.pdf
  56. https://food.ec.europa.eu/food-safety/labelling-and-nutrition/nutrition-and-health-claims/eu-register-health-claims_en
  57. https://www.europarl.europa.eu/thinktank/en/document/EPRS_STU%282023%29747456
  58. https://food.ec.europa.eu/food-safety/labelling-and-nutrition/nutrition-and-health-claims/evaluation-regulation-nutrition-and-health-claims_en
  59. https://www.canada.ca/en/health-canada/services/technical-documents-labelling-requirements/table-permitted-nutrient-content-statements-claims/table-document.html
  60. https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._870/page-18.html
  61. http://inspection.canada.ca/en/food-labels/labelling/industry/health-claims
  62. https://www.foodstandards.gov.au/consumer/labelling/nutrition
  63. https://www.foodstandards.gov.au/business/labelling/nutrition-health-and-related-claims
  64. https://www.mhlw.go.jp/english/topics/foodsafety/fhc/
  65. https://insightplus.bakermckenzie.com/bm/consumer-goods-retail_1/japan-amended-food-labeling-standards-revising-the-foods-with-functional-claims-system
  66. https://food.chemlinked.com/foodpedia/china-health-food-regulation
  67. https://www.nutraingredients.com/Article/2025/04/30/china-may-add-joint-health-support-into-list-of-approved-claims/
  68. https://www.asa.org.uk/advice-online/food-health-claims.html
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC10887619/
  70. https://www.fao.org/4/y2770e/y2770e05.htm
  71. https://www.fao.org/4/y2770e/y2770e07.htm
  72. https://www.fda.gov/food/dietary-supplements
  73. https://www.ftc.gov/news-events/news/press-releases/2020/03/ftc-fda-send-warning-letters-seven-companies-about-unsupported-claims-products-can-treat-or-prevent
  74. https://www.nutraingredients.com/Article/2016/11/04/German-impact-study-finds-EU-health-claim-laws-blocking-innovation-no-excuse-for-lame-marketing-says-analyst/
  75. https://www.ucd.ie/nnsc/t4media/Health%2520Claims%2520Regulations_comparison%2520between%2520USA%2C%2520Japan%2520and%2520the%2520European%2520Union..pdf
  76. https://www.cato.org/cato-journal/spring/summer-2011/markets-tort-law-regulation-achieve-safety
  77. https://www.supplysidesj.com/supplement-regulations/study-suggests-consumers-misunderstand-supplement-health-claims
  78. https://www.heritage.org/government-regulation/report/the-fda-must-stop-its-overreach-and-start-respecting-consumer-freedom
  79. https://www.mdpi.com/2072-6643/15/2/476
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC10195435/
  81. https://oig.hhs.gov/reports/all/2012/dietary-supplements-structurefunction-claims-fail-to-meet-federal-requirements/
  82. https://www.ftc.gov/news-events/news/press-releases/2010/07/dietary-supplement-maker-pay-55-million-settle-ftc-false-advertising-charges
  83. https://www.health.harvard.edu/blog/court-ruling-curbs-unfounded-claims-for-memory-supplement-201905311887
  84. https://www.fda.gov/consumers/health-fraud-scams/warning-letters-health-fraud
  85. https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database
  86. https://www.gao.gov/assets/a295200.html
  87. https://www.foodnavigator.com/News/Promotional-features/substantiating-science-backed-health-claims-for-fb-manufacturers/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC5867125/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC12219162/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC5793269/
  91. https://www.canada.ca/en/health-canada/services/food-nutrition/food-labelling/health-claims/nutraceuticals-functional-foods-health-claims-foods-policy-paper.html
  92. https://www.mdpi.com/2304-8158/14/13/2328
  93. https://health-policy-systems.biomedcentral.com/articles/10.1186/s12961-018-0362-5
  94. https://link.springer.com/article/10.1007/s44187-025-00437-z
  95. https://www.sciencedirect.com/science/article/pii/S2001037024001107
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC11110258/
  97. https://www.newsweek.com/parents-tricked-unhealthy-baby-food-us-grocery-stores-1941632
  98. https://uconnruddcenter.org/wp-content/uploads/sites/2909/2020/09/BabyFoodFACTS_FINAL.pdf
  99. https://www.aafp.org/pubs/afp/issues/2015/1001/p577.html
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC7147696/
  101. https://www1.racgp.org.au/ajgp/2022/august/probiotics-for-infantile-colic
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC8581741/
  103. https://www.bmj.com/content/380/bmj-2022-071075
  104. https://www.cnn.com/2024/08/21/health/unhealthy-baby-food-study-wellness
  105. https://www.who.int/news/item/22-02-2022-more-than-half-of-parents-and-pregnant-women-exposed-to-aggressive-formula-milk-marketing-who-unicef
  106. https://bmjopen.bmj.com/content/10/2/e035405
  107. https://straitsresearch.com/report/functional-food-market
  108. https://www.crnusa.org/resources/economic-impact-study-dietary-supplement-industry
  109. https://pgeconomics.co.uk/press%2Breleases/12/Health%2BClaims%2BRegulation%2Bto%2Bcause%2Bsignificant%2Bnegative%2Beconomic%2Bimpacts
  110. https://www.pgeconomics.co.uk/pdf/Impact-Assessment-health-claims.pdf
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC4330827/
  112. https://market.us/report/global-functional-food-and-nutraceuticals-market/
Add your contribution
Related Hubs
User Avatar
No comments yet.